March 2023. Volume 19. Number 1

Dulaglutide could be a safe and effective treatment alternative in adolescents with type 2 diabetes mellitus

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher Berry C, Barrientos Pérez M, et al; AWARD-PEDS Investigators. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med. 2022;387:433-43.

Reviewers: Rivero Martín MJ1, Fraile Astorga G2.
1Servicio de Pediatría. Hospital Universitario de Fuenlabrada. Fuenlabrada. Madrid. España.
2Pediatra. CS Portillo. Valladolid. España.
Correspondence: M.ª José Rivero Martín. Email: mriverom@salud.madrid.org
Reception date: 26/12/2022
Acceptance date: 09/01/2023
Publication date: 18/01/2023

Abstract

Authors´ conclusions: treatment with dulaglutide at a once-weekly dose of 0,75 mg or 1,5 mg was superior to placebo in improving glycemic control through 26 weeks among youths 10 to 17 years old with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI (body-mass index).

Reviewers´ commentary: treatment with dulaglutide among adolescents with type 2 diabetes is effective versus placebo with or without prior treatment. Given its high economic cost compared to metformin, it could be used as an alternative to treatment failure with metformin rather than as a first line option.

How to cite this article

Rivero Martín MJ, Fraile Astorga G. Dulaglutida podría ser una alternativa de tratamiento segura y eficaz en adolescentes con diabetes mellitus tipo 2. Evid Pediatr. 2023;19:2.

AVC | Critically appraised articles

Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher Berry C, Barrientos Pérez M, et al; AWARD-PEDS Investigators. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med. 2022;387:433-43.

Reviewers: Rivero Martín MJ1, Fraile Astorga G2.
1Servicio de Pediatría. Hospital Universitario de Fuenlabrada. Fuenlabrada. Madrid. España.
2Pediatra. CS Portillo. Valladolid. España.
Correspondence: M.ª José Rivero Martín. Email: mriverom@salud.madrid.org
Reception date: 26/12/2022
Acceptance date: 09/01/2023
Publication date: 18/01/2023

How to cite this article

Rivero Martín MJ, Fraile Astorga G. Dulaglutida podría ser una alternativa de tratamiento segura y eficaz en adolescentes con diabetes mellitus tipo 2. Evid Pediatr. 2023;19:2.

18/01/2023

Linked Comment